Additionally, BPC 157 did not demonstrate any genetic or embryo-fetal toxicity during safety evaluations, ensuring that it does not pose significant risks to genetic integrity or fetal development
Moreover, Johannesson et al
These often improve over time, but your provider will monitor how youre doing and make adjustments if needed
Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial
They sit on shelves for months, even years, with minimal degradation
If your genetic report shows high genetic predisposition to weight regain, your PlexusDx provider may recommend a slower taper, lower target for discontinuation, or transition to a microdose maintenance protocol ($129/mo) rather than full cessation